Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Piamprilimab and Radiotherapy for Neoadjuvant Treatment of Soft Tissue Sarcoma
NCT05718778Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Open-label, single-arm trial of penpulimab in soft tissue sarcoma (STS), sponsored by Henan Cancer Hospital. Primary endpoint: Pathological Complete Response Rate at 12 weeks. Started Mar 2023; status: recruiting.
02
Drugs
penpulimab
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT05718778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05718778.